TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1928685

Group type: EXPERIMENTAL
Intervention: Verrill technique
Number of subjects: 48

Group type: COMPARATOR
Intervention: Glasgow Dental Hospital technique
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 48
Study: 7041522

Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D3 (0.5 micrograms daily)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 30621673

Group type: EXPERIMENTAL
Intervention: Diet intervention (D-group)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control (C-group)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 110
Study: 28372661

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 150

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 150
Study: 26545203

Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium longum subsp. infantis
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 24572293

Group type: EXPERIMENTAL
Intervention: G207 (oncolytic HSV-1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: G207 (oncolytic HSV-1) + 5 Gy radiation
Number of subjects: 9
Study: 22828022

Group type: EXPERIMENTAL
Intervention: Acupressure at true points (third eye and Shen men)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo acupressure at sham points
Number of subjects: 70
Study: 19660001

Group type: EXPERIMENTAL
Intervention: Generic A
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Generic B
Number of subjects: 24

Group type: COMPARATOR
Intervention: Branded amoxicillin
Number of subjects: 24
Study: 17551492

Group type: EXPERIMENTAL
Intervention: Preoperative patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant radiotherapy or adjuvant combined chemo-radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Post-treatment groups (adjuvant therapy)
Number of subjects: 0
Study: 15292307

Group type: EXPERIMENTAL
Intervention: Jugular venous sampling (JVS)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Inferior petrosal sinus sampling (IPSS)
Number of subjects: 88
Study: 11472320

Group type: EXPERIMENTAL
Intervention: Active treatment with ranitidine (300 mg), amoxicillin (1000 mg), and clarithromycin (500 mg) for 7 days
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 129
Study: 9493257

Group type: EXPERIMENTAL
Intervention: Anti-hypertensive treatment A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anti-hypertensive treatment B
Number of subjects: 0
Study: 7931701

Group type: EXPERIMENTAL
Intervention: Folic acid (0.65 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vitamin B‐12 (0.4 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vitamin B‐6 (10 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of folic acid, vitamin B‐12, and vitamin B‐6
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 3348139

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) oral spray
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31121013

Group type: EXPERIMENTAL
Intervention: Doravirine (DOR) 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Darunavir plus ritonavir (DRV+r)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 0
Study: 31070574

Group type: EXPERIMENTAL
Intervention: Plaster fixation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Kirschner wire transfixation
Number of subjects: 38
Study: 29018070

Group type: EXPERIMENTAL
Intervention: Hypothermic oxygenated machine perfusion (HOPE) for 1-2 hours via the portal vein before implantation
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional cold storage (control)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: HOPE
Number of subjects: 46
Study: 26251958

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 100 μg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 μg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 35
Study: 23320428

Group type: EXPERIMENTAL
Intervention: Nutritional consultation by dietitians
Number of subjects: 537

Group type: COMPARATOR
Intervention: No nutritional consultation (Control)
Number of subjects: 537
Study: 21280077

Group type: COMPARATOR
Intervention: Glatiramer acetate 20 mg
Number of subjects: 1155

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate 40 mg
Number of subjects: 1155

Group type: EXPERIMENTAL
Intervention: Both doses (20 mg and 40 mg)
Number of subjects: 1155
Study: 19878986

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 2766

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily as tolerated)
Number of subjects: 2766

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2766
Study: 16861405

Group type: EXPERIMENTAL
Intervention: RA plus clonidine 1 microg/kg as the initial loading dose followed by 1 microg.kg(‐1).h(‐1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: RA plus placebo
Number of subjects: 80
Study: 12611558

Group type: EXPERIMENTAL
Intervention: Oral fenugreek seed powder
Number of subjects: 0
Study: 10390546

Group type: EXPERIMENTAL
Intervention: Vgamma9/Vdelta2 T lymphocytes from cerebrospinal fluid (CSF) of TBM patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vgamma9/Vdelta2 T cells from CSF of TBM children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro expansion of Vgamma9/Vdelta2 T cells from CSF and peripheral blood of TBM patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proportion of ex vivo unstimulated Vgamma9/Vdelta2 T cells in CSF of TBM patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vdelta2 CDR3 TCR analysis of remaining Vdelta2 cells in CSF of TBM patients
Number of subjects: 0
Study: 8522715

Group type: EXPERIMENTAL
Intervention: E4031
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: dofetilide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MS551
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d-sotalol
Number of subjects: 0
Study: 2051152

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both medications
Number of subjects: 60
Study: 6297870

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy with 6000 rad
Number of subjects: 142

Group type: COMPARATOR
Intervention: No postoperative radiotherapy
Number of subjects: 142
Study: 30887761

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 80
Study: 30703441

Group type: EXPERIMENTAL
Intervention: CyclASol 0.05%
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: CyclASol 0.1%
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Restasis
Number of subjects: 207

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 207
Study: 28968167

Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg plus cisplatin 75 mg/m2 plus pemetrexed 500 mg/m2
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo plus cisplatin 75 mg/m2 plus pemetrexed 500 mg/m2
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Gefitinib plus chemotherapy in T790M mutation-positive patients
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Gefitinib plus chemotherapy in T790M mutation-negative patients
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy in T790M mutation-negative patients
Number of subjects: 265
Study: 24690021

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 23408495

Group type: EXPERIMENTAL
Intervention: Intravenous carbamazepine (CBZ) 100 mg dose as partial replacement of morning dose
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Intravenous carbamazepine (CBZ) 100 mg dose
Number of subjects: 113
Study: 21069518

Group type: EXPERIMENTAL
Intervention: Oxymetazoline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Xylometazoline
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (physiological saline)
Number of subjects: 30
Study: 19394661

Group type: EXPERIMENTAL
Intervention: rosiglitazone 8 mg/d
Number of subjects: 27

Group type: COMPARATOR
Intervention: glyburide 10 mg/d
Number of subjects: 27
Study: 17076326

Group type: COMPARATOR
Intervention: Clearfil SE Bond control (SE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clearfil Protect Bond control (PB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primer[SE]/Adhesive[PB]
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primer[PB]/Adhesive[SE]
Number of subjects: 0
Study: 15658652

Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng injection (SFI) plus conventional therapy (mainly glucocorticoids)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional therapy (mainly glucocorticoids)
Number of subjects: 80
Study: 11178762

Group type: COMPARATOR
Intervention: Repair of incidental defects during laparoscopic TAPP repair (Control group: 16 patients)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: No repair of incidental defects during laparoscopic TAPP repair (Trial group: 21 patients)
Number of subjects: 32
Study: 9603590

Group type: EXPERIMENTAL
Intervention: 3 mg bromazepam
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: 6 mg bromazepam
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: 0.5 mg alprazolam
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: 5 mg diazepam
Number of subjects: 376

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 376
Study: 7825081

Group type: EXPERIMENTAL
Intervention: Evacuation under systemic analgesia (fentanyl and midazolam)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Evacuation under general anaesthesia
Number of subjects: 142
Study: 3137608

Group type: COMPARATOR
Intervention: 0.1 mg/kg diazepam
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg diazepam
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg diazepam
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 30623096

Group type: EXPERIMENTAL
Intervention: bococizumab 150, 300, or 450 mg co‐mixed with rHuPH20
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: bococizumab 300 mg + rHuPH20
Number of subjects: 60

Group type: COMPARATOR
Intervention: bococizumab 300 mg alone
Number of subjects: 60
Study: 26943336

Group type: EXPERIMENTAL
Intervention: Mesh-augmented reinforcement with large-pore polypropylene mesh (Ultrapro, width 7.5 cm)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional closure
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mesh-augmented reinforcement
Number of subjects: 120
Study: 25716365

Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Test foods (15 Southeast Asian foods)
Number of subjects: 47
Study: 24385633

Group type: EXPERIMENTAL
Intervention: Demographics and health conditions (younger age, increased education, White race)
Number of subjects: 2782

Group type: EXPERIMENTAL
Intervention: Male gender, diabetes, suspected clinical depression
Number of subjects: 2782

Group type: EXPERIMENTAL
Intervention: Suspected clinical depression
Number of subjects: 2782

Group type: EXPERIMENTAL
Intervention: Diabetes and history of stroke
Number of subjects: 2782
Study: 20463587

Group type: EXPERIMENTAL
Intervention: Standard regimen (clear liquid diet, 4 L of PEG, and 1 or 2 NaP boosters)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Modified regimen (1 or 2 PEG boosters, 4 senna tablets, and a low-residue diet)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Standard regimen
Number of subjects: 40

Group type: COMPARATOR
Intervention: Modified regimen
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 40
Study: 19356075

Group type: EXPERIMENTAL
Intervention: Cyclosporine (single oral dose)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: ABCB1 genotypes
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: ABCB1 haplotypes
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cyclosporine PBMC pharmacokinetics
Number of subjects: 87
Study: 17069542

Group type: EXPERIMENTAL
Intervention: CX516
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 12552363

Group type: EXPERIMENTAL
Intervention: Hydrocodone bitartrate (7.5 mg) plus ibuprofen (200 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Ibuprofen alone
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 11180025

Group type: EXPERIMENTAL
Intervention: Mizolastine 5 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mizolastine 15 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mizolastine 20 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9365149

Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 mg by mouth twice a day for eight weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 1506656

Group type: EXPERIMENTAL
Intervention: Vasopressin (0.66 units/min)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ketanserin (10 mg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Vasopressin plus Ketanserin
Number of subjects: 33
Study: 7309410

Group type: EXPERIMENTAL
Intervention: Recall associates produced five minutes later
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recall associates produced 24 hours later
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial association task with emotional words
Number of subjects: 0
Study: 31037562

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily for 8 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Everolimus 5 mg daily for 8 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Everolimus (both doses)
Number of subjects: 17
Study: 25418187

Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 925

Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 925

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 925
Study: 23663001

Group type: EXPERIMENTAL
Intervention: Perampanel 4 mg
Number of subjects: 1478

Group type: EXPERIMENTAL
Intervention: Perampanel 8 mg
Number of subjects: 1478

Group type: EXPERIMENTAL
Intervention: Perampanel 12 mg
Number of subjects: 1478

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1478
Study: 21896132

Group type: EXPERIMENTAL
Intervention: 10% glycolic acid containing oil-in-water emulsion applied once daily in the evening for 90 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 19219442

Group type: EXPERIMENTAL
Intervention: Local injection of a steroid (1 mL triamcinolone) combined with local anaesthetic (1 mL lidocaine) in group A
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Injection of local anaesthetic (1 mL lidocaine) combined with peppering technique in group B
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Local injection of a steroid (1 mL triamcinolone) combined with local anaesthetic (1 mL lidocaine) and peppering technique in group C
Number of subjects: 75

Group type: COMPARATOR
Intervention: Comparison of group C to group A
Number of subjects: 75

Group type: COMPARATOR
Intervention: Comparison of group C to group B
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: VAS pain measurement at 6 months for all groups
Number of subjects: 75
Study: 17849682

Group type: EXPERIMENTAL
Intervention: Perioe Cavity Care by LG Care, Korea
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Colgate Total by Colgate‐Palmolive, Thailand
Number of subjects: 3

Group type: COMPARATOR
Intervention: Vicco by Vicco Labs, India
Number of subjects: 3
Study: 16565915

Group type: EXPERIMENTAL
Intervention: Community Re‐entry Module (CRM)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Supportive Counseling (SC)
Number of subjects: 96
Study: 14523786

Group type: EXPERIMENTAL
Intervention: Subcutaneously administered recombinant interleukin-2 (rIL-2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiretroviral therapy without rIL-2 (Control)
Number of subjects: 0
Study: 9890319

Group type: EXPERIMENTAL
Intervention: Intermittent treatment with glycopeptide (vancomycin or teicoplanin) and ceftazidime
Number of subjects: 152

Group type: COMPARATOR
Intervention: Continuous treatment with glycopeptide (vancomycin or teicoplanin) and ceftazidime
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Intermittent ceftazidime treatment
Number of subjects: 152

Group type: COMPARATOR
Intervention: Continuous ceftazidime treatment
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Intermittent treatment with glycopeptide and ceftazidime
Number of subjects: 152

Group type: COMPARATOR
Intervention: Continuous treatment with glycopeptide and ceftazidime
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Intermittent and continuous treatment
Number of subjects: 152
Study: 7752906

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 1,200 mg daily for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 20
Study: 2267193

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Fenactil, Torecan, Aviomarin, Primperan
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7011237

Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Amiloride plus hydrochlorothiazide
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 179
Study: 31866419

Group type: EXPERIMENTAL
Intervention: Powerful Tools for Caregivers (PTC) intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 60
Study: 31129681

Group type: EXPERIMENTAL
Intervention: Praziquantel treatment during pregnancy
Number of subjects: 359

Group type: COMPARATOR
Intervention: Placebo treatment during pregnancy
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Maternal non-iron-deficiency anemia (NIDA)
Number of subjects: 359
Study: 26099028

Group type: EXPERIMENTAL
Intervention: Cryolipolysis
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (contralateral untreated flanks)
Number of subjects: 11
Study: 23756830

Group type: EXPERIMENTAL
Intervention: Fatigue condition
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 10
Study: 21858548

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5 mg elemental Zn per day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 18269665

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied to one side of the operation area for 7 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no LLLT applied)
Number of subjects: 20
Study: 16439173

Group type: EXPERIMENTAL
Intervention: Clonidine 1.5 microg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Clonidine 3.0 microg/kg
Number of subjects: 6
Study: 14669620

Group type: EXPERIMENTAL
Intervention: roncoleukin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: betaleukin
Number of subjects: 100
Study: 11323998

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zinc oxide eugenol
Number of subjects: 0
Study: 8781939

Group type: EXPERIMENTAL
Intervention: Epinephrine alone
Number of subjects: 160

Group type: COMPARATOR
Intervention: Epinephrine plus absolute alcohol
Number of subjects: 160
Study: 1626795

Group type: EXPERIMENTAL
Intervention: Nasal administration of beclamethasone dipropionate (400 micrograms total, 100 micrograms four times per day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Bronchial administration of beclamethasone dipropionate (400 micrograms total, 100 micrograms four times per day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (administered into the nose when B was administered into the bronchi and vice versa)
Number of subjects: 11
Study: 6359846

Group type: EXPERIMENTAL
Intervention: pirbuterol (n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: pirbuterol after 3 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo (n = 10)
Number of subjects: 20
Study: 30576716

Group type: EXPERIMENTAL
Intervention: All-extremity high-intensity interval training (HIIT)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Non-exercise control (CONT)
Number of subjects: 58
Study: 29697876

Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg/d)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Platinum-based therapy plus pemetrexed (500 mg/m2)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 63

Group type: COMPARATOR
Intervention: Platinum-based therapy plus pemetrexed
Number of subjects: 63
Study: 27492510

Group type: EXPERIMENTAL
Intervention: Angiopoietin-2 (Ang‐2) serum levels in AE‐IIPs patients
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Angiopoietin-2 (Ang‐2) serum levels in ALI/ARDS patients
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Correlation of Ang‐2 levels with CRP in AE‐IIPs patients
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Correlation of Ang‐2 levels with CRP and SOFA scores in ALI/ARDS patients
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Ang‐2 levels in survivors during treatment
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Ang‐2 levels in non-survivors
Number of subjects: 111